Appendix 2 Quality assessment tools. Cochrane risk of bias tool for RCTs. Support for judgment

Similar documents
Online Supplementary Material

Instrument for the assessment of systematic reviews and meta-analysis

Tool to Assess Risk of Bias in Cohort Studies

NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES

GATE CAT Intervention RCT/Cohort Studies

Supplement DS1 Search strategy. EMBASE Search Strategy

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.

RATING OF A RESEARCH PAPER. By: Neti Juniarti, S.Kp., M.Kes., MNurs

Systematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)

Guidelines for Reporting Non-Randomised Studies

Controlled Trials. Spyros Kitsiou, PhD

GATE CAT Case Control Studies

Cochrane Pregnancy and Childbirth Group Methodological Guidelines

1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010)

ARCHE Risk of Bias (ROB) Guidelines

Assessing risk of bias

Systematic Reviews and Meta- Analysis in Kidney Transplantation

GATE CAT Diagnostic Test Accuracy Studies

LIHS Mini Master Class

CONSORT 2010 checklist of information to include when reporting a randomised trial*

1. exp Narcotics/ or exp Opiate Alkaloids/ or exp Fentanyl/ or exp meperidine/ or exp Morphine Derivatives/ or exp Methadone/

Supporting information for Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative

First author. Title: Journal

Appendix. TABLE E-1 Search Terms

A Systematic Review of the Efficacy and Clinical Effectiveness of Group Analysis and Analytic/Dynamic Group Psychotherapy

SUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*

Randomized Controlled Trial

Evidence Based Medicine

ISPOR Task Force Report: ITC & NMA Study Questionnaire

Systematic Reviews and Meta-analysis in Aquatic therapy

HTA Systematic review of treatment of dry age-related macular degeneration and Stargardt disease.

Overview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools: Opportunities and Challenges of Application in Developing DRIs

Alcohol interventions in secondary and further education

GRADE, Summary of Findings and ConQual Workshop

University of Bristol - Explore Bristol Research

Introduzione al metodo GRADE

APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES

Can we teach how to discriminate between good & bad evidence? the GATE approach

Protocol Development: The Guiding Light of Any Clinical Study

Graft nephrectomy for people with a failed kidney transplant(protocol)

Maxing out on quality appraisal of your research: Avoiding common pitfalls. Policy influenced by study quality

USDA Nutrition Evidence Library: Systematic Review Methodology

Appendix 1: Supplementary tables [posted as supplied by author]

The QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews

NQF-Endorsed Measures for Endocrine Conditions: Cycle 2, 2014

Why is ILCOR moving to GRADE?

Appendices. Appendix A Search terms

Supplementary material

School of Dentistry. What is a systematic review?

Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

Time of onset and predictors of biphasic anaphylactic reactions: A systematic. A. To describe the time frame where biphasic reactions can occur.

CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG)

Setting The setting was hospital and the economic analysis was carried out in the Netherlands.

Introductory: Coding

Mapping the Informed Health Choices (IHC) Key Concepts (KC) to core concepts for the main steps of Evidence-Based Health Care (EBHC).

Quantitative research Quiz Answers

User s guide to the checklist of items assessing the quality of randomized controlled trials of nonpharmacological treatment

Critical Appraisal of RCT

Downloaded from:

The role of Randomized Controlled Trials

Cochrane Breast Cancer Group

Standard Methods for Quality Assessment of Evidence

Checklist for Randomized Controlled Trials. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews

Appendix Document A1: Search strategy for Medline (1960 November 2015)

Z-drugs and risk of falls and fractures: A systematic review and metaanalysis

Critical Appraisal Tools

The Effective Public Health Practice Project Tool

Appendix A: Literature search strategy

Checklist for Randomized Controlled Trials. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews

Online Appendices Online Appendix 1 Online Appendix 2 Online Appendix 3a Online Appendix 3b Online Appendix 3c Online Appendix 4 Online Appendix 5

1 Case Control Studies

MINDFULNESS-BASED INTERVENTIONS IN EPILEPSY

Issues to Consider in the Design of Randomized Controlled Trials

Influence of blinding on treatment effect size estimate in randomized controlled trials of oral health interventions

Determinants of quality: Factors that lower or increase the quality of evidence

Copyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD

CHECKLIST FOR EVALUATING A RESEARCH REPORT Provided by Dr. Blevins

CHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S

TEST YOURSELF: Multiple Choice 1 QUESTIONS

American Journal of Internal Medicine

CONSORT: missing missing data guidelines, the effects on HTA monograph reporting Yvonne Sylvestre

Study Design STUDY DESIGN CASE SERIES AND CROSS-SECTIONAL STUDY DESIGN

Review Standards and Methods for Quality Assessment of Evidence

Jelena Savović 1*, Laura Weeks 2, Jonathan AC Sterne 1, Lucy Turner 3, Douglas G Altman 4, David Moher 3,5 and Julian PT Higgins 1,6

Mapping from SORT to GRADE. Brian S. Alper, MD, MSPH, FAAFP Editor-in-Chief, DynaMed October 31, 2013

Study population The study population comprised patients who had undergone major abdominal surgery in routine care.

Meta-analyses: analyses:

EER Assurance Criteria & Assertions IAASB Main Agenda (June 2018)

PROSPERO International prospective register of systematic reviews

BEST in MH clinical question-answering service

A response by Servier to the Statement of Reasons provided by NICE

Template for MECIR (Review)

Feng-Yi Lai, RN, MSN, Instructor Department of Nursing, Shu-Zen College of Medicine and Management, Asphodel Yang, RN, PhD, Associate Professor

Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis

Guideline Development (CBO)

Memo. CSAC Action Required. Background. Draft Report. October 23, 2018

Pilot & Feasibility Randomized Controlled Trials

EQUATOR Network: promises and results of reporting guidelines

Transcription:

Appendix 2 Quality assessment tools Cochrane risk of bias tool for RCTs Item Judgment (H/L/Unclear) Random sequence generation (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (performance bias) Blinding of outcome assessment (detection bias) Incomplete outcome data addressed (attrition bias) Selective reporting (reporting bias) Other bias Support for judgment Quote Comment

Newcastle-Ottawa Scale (NOS) for Case-control Studies SELECTION 1) Is the Case Definition Adequate? a) Requires some independent validation (e.g. >1 person/record/time/process to extract information, or reference to primary record source such as x-rays or medical/hospital records) b) Record linkage (e.g. ICD codes in database) or self-report with no reference to primary record c) No description 2) Representativeness of the Cases a) All eligible cases with outcome of interest over a defined period of time, all cases in a defined catchment area, all cases in a defined hospital or clinic, group of hospitals, health maintenance organisation, or an appropriate sample of those cases (e.g. random sample) b) Not satisfying requirements in part (a), or not stated. 3) Selection of Controls This item assesses whether the control series used in the study is derived from the same population as the cases and essentially would have been cases had the outcome been present. a) Community controls (i.e. same community as cases and would be cases if had outcome) b) Hospital controls, within same community as cases (i.e. not another city) but derived from a hospitalised population c) No description 4) Definition of Controls a) If cases are first occurrence of outcome, then it must explicitly state that controls have no history of this outcome. If cases have new (not necessarily first) occurrence of outcome, then controls with previous occurrences of outcome of interest should not be excluded. b) No mention of history of outcome

COMPARABILITY 1) Comparability of Cases and Controls on the Basis of the Design or Analysis A maximum of 2 stars can be allotted in this category Either cases and controls must be matched in the design and/or confounders must be adjusted for in the analysis. Statements of no differences between groups or that differences were not statistically significant are not sufficient for establishing comparability. Note: If the odds ratio for the exposure of interest is adjusted for the confounders listed, then the groups will be considered to be comparable on each variable used in the adjustment. There may be multiple ratings for this item for different categories of exposure (e.g. ever vs. never, current vs. previous or never) Age =, Other controlled factors = EXPOSURE 1) Ascertainment of Exposure 2) Non-Response Rate

Newcastle-Ottawa Scale (NOS) for Cohort Studies SELECTION 1) Representativeness of the Exposed Cohort Item is assessing the representativeness of exposed individuals in the community, not the representativeness of the sample of women from some general population. For example, subjects derived from groups likely to contain middle class, better educated, health oriented women are likely to be representative of postmenopausal estrogen users while they are not representative of all women (e.g. members of a health maintenance organisation (HMO) will be a representative sample of estrogen users. While the HMO may have an under-representation of ethnic groups, the poor, and poorly educated, these excluded groups are not the predominant users users of estrogen). 2) Selection of the Non-Exposed Cohort 3) Ascertainment of Exposure 4) Demonstration That Outcome of Interest Was Not Present at Start of Study In the case of mortality studies, outcome of interest is still the presence of a disease/ incident, rather than death. That is to say that a statement of no history of disease or incident earns a star. COMPARABILITY 1) Comparability of Cohorts on the Basis of the Design or Analysis A maximum of 2 stars can be allotted in this category Either exposed and non-exposed individuals must be matched in the design and/or confounders must be adjusted for in the analysis. Statements of no differences between groups or that differences were not statistically significant are not sufficient for establishing comparability. Note: If the relative risk for the exposure of interest is adjusted for the confounders listed, then the groups will be considered to be comparable on each variable used in the adjustment.

There may be multiple ratings for this item for different categories of exposure (e.g. ever vs. never, current vs. previous or never) Age =, Other controlled factors = OUTCOME 1) Assessment of Outcome For some outcomes (e.g. fractured hip), reference to the medical record is sufficient to satisfy the requirement for confirmation of the fracture. This would not be adequate for vertebral fracture outcomes where reference to x-rays would be required. a) Independent or blind assessment stated in the paper, or confirmation of the outcome by reference to secure records (x-rays, medical records, etc.) b) Record linkage (e.g. identified through ICD codes on database records) c) Self-report (i.e. no reference to original medical records or x-rays to confirm the outcome) d) No description. 2) Was Follow-Up Long Enough for Outcomes to Occur An acceptable length of time should be decided before quality assessment begins (e.g. 5 yrs. for exposure to breast implants) 3) Adequacy of Follow Up of Cohorts This item assesses the follow-up of the exposed and non-exposed cohorts to ensure that losses are not related to either the exposure or the outcome.

Quality Assessment Tool for Cross-Sectional Studies Criteria Yes No Other (CD, NR, NA)* 1. Was the research question or objective in this paper clearly stated? 2. Was the study population clearly specified and defined? 3. Was the participation rate of eligible persons at least 50%? 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? 5. Was a sample size justification, power description, or variance and effect estimates provided? 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 10. Was the exposure(s) assessed more than once over time? 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across

all study participants? 12. Were the outcome assessors blinded to the exposure status of participants? 13. Was loss to follow-up after baseline 20% or less? 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? Quality Rating (Good, Fair, or Poor) (see guidance) Rater #1 initials: Rater #2 initials: Additional Comments (If POOR, please state why): *CD, cannot determine; NA, not applicable; NR, not reported

Quality Assessment Tool for Case Series Studies Criteria Yes No Other (CD, NR, NA)* 1. Was the study question or objective clearly stated? 2. Was the study population clearly and fully described, including a case definition? 3. Were the cases consecutive? 4. Were the subjects comparable? 5. Was the intervention clearly described? 6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants? 7. Was the length of follow-up adequate? 8. Were the statistical methods well-described? 9. Were the results well-described? Quality Rating (Good, Fair, or Poor) Rater #1 initials: Rater #2 initials: Additional Comments (If POOR, please state why): *CD, cannot determine; NA, not applicable; NR, not reported